RxDoctor Payments Data

Emily Reed, MD

Internal Medicine · Edmond, OKNPI 1942255740

Payments from drug & device makers

$8,226in general payments, 2019–2025

Across 514 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$976
  • Pfizer$908
  • Novo Nordisk$836
  • Lilly USA, LLC$756
  • GSK$449
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$8,220100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,226 in reported general payments places this provider in the 90th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$100,242
Medicare patients
230
Services billed
1,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide180$202,458
EliquisApixaban34$43,010
Nurtec OdtRimegepant Sulfate19$38,562
ProliaDenosumab15$25,621
OzempicSemaglutide20$24,132
FarxigaDapagliflozin Propanediol14$20,013
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,056
OxycontinOxycodone Hcl12$14,939
JardianceEmpagliflozin11$14,794
LinzessLinaclotide21$12,495
RybelsusSemaglutide11$10,290
MyrbetriqMirabegron13$8,585
BelsomraSuvorexant20$8,539
Omeprazole184$4,344
Oxycodone Hcl137$3,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$756$202,458180 claims
PfizerEliquis, Nurtec Odt$908$81,57253 claims
Novo NordiskOzempic, Rybelsus$836$34,42231 claims
AmgenProlia$427$25,62115 claims
AstraZenecaFarxiga$976$20,01314 claims
GSKTrelegy Ellipta$449$16,05618 claims
Boehringer IngelheimJardiance$322$14,79411 claims
AbbVieLinzess$1,161$12,49521 claims
Astellas Pharma US IncMyrbetriq$19$8,58513 claims
MerckBelsomra$269$8,53920 claims
Sanofi-aventis U.S. LLCLantus$126$1,52211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →